View Author
patient imatinib sarcoma cancer trabectedin tumor response study oncol treatment month phase stromal j clin oncol activity mutation therapy disease stromal tumors trial result retrospective analysis kinase translocation-related sarcomas antitumour activity resistance survival phase ii study oncology analysis retrospective tissue inhibitor imatinib mesylate / european journal cesne subtype mrc-l-sarcoma recist factor metastatic synovial sarcoma pharmacokinetic research clin cancer res cesne a.l bene fit antitumour synovial mesylate tyrosine criteria liposarcoma progression myxoid-round cell liposarcoma tissue sarcomas european tissue sarcoma demetri stromal tumor imatinib resistance level trs subtypes tumour translocation stromal tumours eur j cancer chemotherapy change response evaluation criteria research support fusion san filippo r metastatic gist disease control gist patients protein grade oncoprotein demetri gd
3 Most Recent Publications
|
Modifying phase i methodology to facilitate enrolment of molecularly selected patients
(Article)
Hollebecque, A. Postel-Vinay, S. Verweij, J. Demetri, G.D. Flaherty, K.T. Bedard, P. Soria, J.C. |
2013-05-01
|
|
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
(Article)
Cesne, A. le Blay, J-Y. Grosso, F. Lardelli, P. Nieto, A. Alfaro, V. Verweij, J. Poveda, A. Casali, P.G. Demetri, G.D. Cresta, S. Maki, R.G. Balaña, C. Schöffski, P. |
2012-06-29
|
|
Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
(Article)
Benjamin, R.S. Debiec-Rychter, M. Cesne, A. le Sleijfer, S. Demetri, G.D. Joensuu, H. Schöffski, P. Poveda, A. |
2009-08-01
|
